The next 18-24 months will bring critical milestones: major trial results across multiple cardiorenal-metabolic therapeutic classes extending beyond GLP-1s, updated guidelines, and finalised payer policies. Together, these will define how cardiorenal-metabolic disease is treated for years to come.

Like modern football's evolution from rigid formations to fluid, position-less play, cardiorenal-metabolic care is moving from organ-centric to integrated care, with dynamic combination strategies. Success won’t be measured by individual performance but by how effectively the entire therapeutic team works together.

GLP-1s will find their position not by displacing others, but by enhancing multi-drug regimens essential for managing the complex pathophysiology of CKD and HF— supporting patients through personalised, multimodal approaches. The question isn't whether GLP-1s belong, it’s whether we can build systems sophisticated enough to win against cardiorenal-metabolic disease. The organisations that answer this question first will define the standard of care for a generation.